Q-linea strengthens management team

UPPSALA, Sweden, 12 July, 2019 - Q-linea AB (publ) (Nasdaq Stockholm:QLINEA), a diagnostic company focused on developing and delivering solutions to accurately and rapidly diagnose infectious diseases, today announced MD Tiziana Di Martino has been appointed the company’s Chief Medical Officer and will be part of Q-linea’s management team.

Notice of Annual General Meeting in Q-Linea AB (publ)

The shareholders in Q-linea AB (publ), reg. no. 556729-0217 (the “Company”) are hereby convened to the annual general meeting on Wednesday 22 May 2019, at 4 pm in Konferens Hubben (conference room 3+4) with address Dag Hammarskjölds väg 38, 752 37 Uppsala.

Q-linea’s ASTar – a success on ECCMID

Q-linea AB (publ) (OMX: QLINEA), a diagnostic company focused on developing and delivering solutions to accurately and rapidly diagnose infectious diseases, now presents the final design of ASTar for potential customers at the most important trade fair; the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), this year being held in Amsterdam, 13-16 April.

Q-linea can reach its main market faster than planned

Q-linea AB (publ) (OMX: QLINEA), today announced that the company's first product ASTar™ is expected to launch on the company’s main market, the U.S., three to four months than earlier communicated to take advantage of strong market interest and positive feedback from the US Food and Drug Administration, the FDA. The European launch is thus postponed to the same extent.

Stabilization notice and end of the stabilization period

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES